Editorial: Prodromal stage of neurodegenerative proteinopathies: from bench to bedside

Frontiers in Neuroscience

Neuroscience

Bin Xu¹  Yashar Zeighami²  Seyed-Mohammad Fereshtehnejad³ 

[1] Biomanufacturing Research Institute and Technology Enterprise (BRITE), Department of Pharmaceutical Sciences, North Carolina Central University, Durham, NC, United States;Affiliated Faculty, Duke/UNC Alzheimer's Disease Research Center, Durham, NC, United States;Department of Psychiatry, McGill University, Montreal, QC, Canada;Cerebral Imaging Center, Douglas Mental Health University Institute, Verdun, QC, Canada;Movement Disorders Clinic, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada;Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet, Stockholm, Sweden;

关键词: Alzheimer's disease;    Parkinson's disease;    prodromal stage;    proteinopathy;    early biomarkers;    phenoconversion;    mild cognitive impairment (MCI);   

DOI  :  10.3389/fnins.2023.1295344

 received in 2023-09-16, accepted in 2023-09-19,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 Xu, Fereshtehnejad and Zeighami.